Sandip Kapadia - Jan 24, 2025 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Stock symbol
HRMY
Transactions as of
Jan 24, 2025
Transactions value $
-$144,974
Form type
4
Date filed
1/28/2025, 04:04 PM
Previous filing
Jan 23, 2025
Next filing
Apr 1, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $0 +3.81K $0.00 3.81K Jan 24, 2025 Direct
transaction HRMY Common Stock Tax liability -$77.4K -2.04K -53.44% $38.01 1.78K Jan 24, 2025 Direct F1
transaction HRMY Common Stock Sale -$67.5K -1.78K -100% $38.05 0 Jan 27, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Restricted Stock Units Options Exercise $0 -3.81K -25% $0.00 11.4K Jan 24, 2025 Common Stock 3.81K Direct F4
transaction HRMY Stock Option Award $0 +66.3K $0.00 66.3K Jan 25, 2025 Common Stock 66.3K $38.01 Direct F5
transaction HRMY Restricted Stock Units Award $0 +18.9K $0.00 18.9K Jan 25, 2025 Common Stock 18.9K Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.68. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F5 The stock option vests with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F6 . The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.